Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07473544

Essential Oil Inhalation and Acute Stress Response in Healthy Adults

This randomized, double-blind, placebo-controlled study evaluates the acute physiological and subjective responses to essential oil inhalation in healthy adults. Participants are assigned to inhale either an essential oil or a placebo via an aroma stick during standardized laboratory procedures designed to induce temporary psychosocial stress (Trier Social Stress Test - Group version) and during a guided relaxation session.

Physiological responses, including heart rate, heart rate variability, and electrodermal activity, are measured using a wearable sensor. Subjective stress and affect are assessed using validated questionnaires and visual analog scales. The purpose of this study is to characterize short-term autonomic and self-reported responses associated with essential oil inhalation under controlled experimental conditions. This study is exploratory and is not intended to diagnose, treat, or prevent any medical condition.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

dōTERRA International

Pleasant Grove, Utah, 84062, United States

About this study

Essential oils and essential oil blends are widely used in non-clinical settings; however, objective data describing short-term physiological and subjective responses to inhalation under controlled experimental conditions remain limited. This study is designed to evaluate acute autonomic and self-reported responses to essential oil inhalation during standardized laboratory procedures involving psychosocial stress and guided relaxation.

This is a randomized, double-blind, placebo-controlled, parallel-group study conducted in healthy adults aged 18-45 years. Participants are assigned to inhale either an essential oil (or essential oil blend) or a placebo comparator administered via an identical aroma stick. Inhalation occurs at standardized time points during two study visits.

During Study Visit 1, participants undergo the Trier Social Stress Test - Group version (TSST-G), a validated laboratory paradigm designed to induce temporary psychosocial stress through public speaking and mental arithmetic tasks performed under observation. Inhalation occurs during baseline, preparation, stress, and recovery phases. During Study Visit 2, participants undergo a structured guided meditation session under controlled environmental conditions, with inhalation occurring at standardized intervals.

Physiological measures are collected continuously using a wrist-worn wearable device capable of measuring heart rate, heart rate variability (HRV), and electrodermal activity (EDA). Subjective responses are assessed using validated instruments including visual analog scales for stress and calm, PROMIS Anxiety, GAD-7, and PANAS. The primary outcome is change in stress response as measured by area under the curve (AUC) for visual analog scale stress scores across the stress and recovery period.

The study employs an adaptive design with an initial planned enrollment of 100 participants (50 per arm) and a prespecified interim analysis for potential expansion to a maximum of 200 participants. Statistical analyses include comparison of stress and physiological responses between groups using baseline-adjusted models.

This study is exploratory in nature and is intended to characterize acute responses associated with essential oil inhalation under controlled conditions. It is not designed to diagnose, treat, mitigate, or prevent any disease or medical condition.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age 18-45 years, inclusive

Able to read, write, and understand English

Willing and able to provide informed consent

Willing to attend two in-person study visits

Generally healthy, as determined by medical history and screening review

Exclusion criteria

Known asthma, chronic obstructive pulmonary disease (COPD), significant lung disease, heart disease, or other medical condition that may compromise safety or data integrity

Pregnancy or pregnancy within the past 90 days

Known allergy or sensitivity to essential oils or study placebo materials

Current smoking, vaping, chewing tobacco, or use of recreational drugs

Regular use of essential oils applicable to the study phase (>3 times per week for ≥2 weeks within the past month) without a minimum 1-month washout

Unwillingness to abstain from alcohol for at least 72 hours prior to each study visit

Failure to meet inclusion criteria

Treatment and study plan

Essential Oil Inhalation

Other

Participants inhale an essential oil or essential oil blend administered via an individual aroma stick. At prespecified time points during baseline, stress induction (Trier Social Stress Test - Group version), and recovery or guided meditation procedures, participants are instructed to take five normal breaths from the aroma stick. The intervention is delivered in a randomized, double-blind manner and is standardized across participants within each study phase.

Placebo Aroma Stick

Other

Participants inhale a placebo comparator administered via an aroma stick identical in appearance and delivery method to the experimental intervention but without active essential oil components. The inhalation schedule and procedures are identical to those used in the experimental arm to maintain blinding.

Primary outcomes

  1. Change in Visual Analog Scale (VAS) Stress Area Under the Curve (AUC)

    Time frame: Baseline through 30 minutes post-stressor recovery (Study Visit 1)

    Area under the curve (AUC) for self-reported stress measured using a Visual Analog Scale (VAS) across baseline, stress induction (Trier Social Stress Test - Group version), and post-stressor recovery periods. The VAS-stress scale ranges from low stress to high stress, with higher scores indicating greater perceived stress.

Other outcomes

  1. Change in Heart Rate During Stress and Recovery

    Time frame: Baseline through 30 minutes post-stressor recovery (Study Visit 1), approximately 90 minutes from baseline

    Mean heart rate measured using a wearable sensor during baseline, stress induction (Trier Social Stress Test - Group version), and post-stressor recovery. A higher heart rate, measured beats per minute (BPM), indicates higher stress.

  2. Change in Electrodermal Activity During Stress and Recovery

    Time frame: Baseline through 30 minutes post-stressor recovery (Study Visit 1), approximately 90 minutes from baseline.

    Tonic electrodermal activity measured using a wearable sensor during baseline, stress induction, and recovery periods. This is measured in microsiemens, which is the SI unit of conductance. Higher tonic ectodermal activity indicates higher stress.

  3. Change in PROMIS Anxiety Scores

    Time frame: Baseline and post-stressor recovery (Study Visit 1), approximately 90 minutes from baseline.

    PROMIS Anxiety short form scores collected at baseline and during post-stressor recovery to assess subjective anxiety symptoms. A higher score indicates higher anxiety. The measurement scale ranges from 1 ("never") to 5 ("always").

  4. Change in Positive and Negative Affect Schedule (PANAS) Scores

    Time frame: Baseline and post-stressor recovery (Study Visit 1), approximately 90 minutes from baseline

    PANAS scores assessing positive and negative affect collected at baseline and post-stressor recovery. The rating scale ranges from 1 ("Very slightly or not at all") to 5 ("extremely"). Higher scores with regard to the positive affect questions indicate greater levels of joy, enthusiasm, and active engagement. Higher scores with regard to the negative affect questions indicate higher levels of fear, anger, or distress.

  5. Change in Visual Analog Scale (VAS) Calm Scores

    Time frame: Baseline through 30 minutes post-stressor recovery (Study Visit 1), approximately 90 minutes after baseline.

    Self-reported calmness measured using a visual analog scale across baseline, stress, and recovery phases. It is measured on a score of 0 to 100, with 0 representing "Not at all", and 100 representing "extremely".

  6. Incidence of Adverse Events

    Time frame: Through completion of Study Visit 2, up to 1 week post baseline.

    Number and severity of participant-reported adverse events occurring during study visits.

Sponsors and collaborators

Lead sponsor

dōTERRA International

Industry

Registry information

Official study title

Evaluation of Aromatic Essential Oils in Conditions of Stress and Relaxation - A Double-Blind, Randomized, Placebo-Controlled Trial

Acronym: DMA

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Mar 16, 2026
Registry last updated
May 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.